Ligand activation of LXRβ reverses atherosclerosis and cellular cholesterol overload in mice lacking LXRα and apoE

Michelle N. Bradley, Cynthia Hong, Mingyi Chen, Sean B. Joseph, Damien C. Wilpitz, Xuping Wang, Aldons J. Lusis, Allan Collins, Willa A. Hseuh, Jon L. Collins, Rajendra K. Tangirala, Peter Tontonoz

Research output: Contribution to journalArticle

196 Citations (Scopus)

Abstract

Liver X receptors (LXRs) α and β are transcriptional regulators of cholesterol homeostasis and potential targets for the development of antiatherosclerosis drugs. However, the specific roles of individual LXR isotypes in atherosclerosis and the pharmacological effects of synthetic agonists remain unclear. Previous work has shown that mice lacking LXRα accumulate cholesterol in the liver but not in peripheral tissues. In striking contrast, we demonstrate here that LXRα-/-apoE-/- mice exhibit extreme cholesterol accumulation in peripheral tissues, a dramatic increase in whole-body cholesterol burden, and accelerated atherosclerosis. The phenotype of these mice suggests that the level of LXR pathway activation in macrophages achieved by LXRβ and endogenous ligand is unable to maintain homeostasis in the setting of hypercholesterolemia. Surprisingly, however, a highly efficacious synthetic agonist was able to compensate for the loss of LXRα. Treatment of LXRα-/-apoE-/- mice with synthetic LXR ligand ameliorates the cholesterol overload phenotype and reduces atherosclerosis. These observations indicate that LXRα has an essential role in maintaining peripheral cholesterol homeostasis in the context of hypercholesterolemia and provide in vivo support for drug development strategies targeting LXRβ.

Original languageEnglish (US)
Pages (from-to)2337-2346
Number of pages10
JournalJournal of Clinical Investigation
Volume117
Issue number8
DOIs
StatePublished - Aug 1 2007

Fingerprint

Apolipoproteins E
Atherosclerosis
Cholesterol
Ligands
Homeostasis
Hypercholesterolemia
Liver X Receptors
Body Burden
Phenotype
Macrophage Activation
Pharmaceutical Preparations
Pharmacology

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bradley, M. N., Hong, C., Chen, M., Joseph, S. B., Wilpitz, D. C., Wang, X., ... Tontonoz, P. (2007). Ligand activation of LXRβ reverses atherosclerosis and cellular cholesterol overload in mice lacking LXRα and apoE. Journal of Clinical Investigation, 117(8), 2337-2346. https://doi.org/10.1172/JCI31909

Ligand activation of LXRβ reverses atherosclerosis and cellular cholesterol overload in mice lacking LXRα and apoE. / Bradley, Michelle N.; Hong, Cynthia; Chen, Mingyi; Joseph, Sean B.; Wilpitz, Damien C.; Wang, Xuping; Lusis, Aldons J.; Collins, Allan; Hseuh, Willa A.; Collins, Jon L.; Tangirala, Rajendra K.; Tontonoz, Peter.

In: Journal of Clinical Investigation, Vol. 117, No. 8, 01.08.2007, p. 2337-2346.

Research output: Contribution to journalArticle

Bradley, MN, Hong, C, Chen, M, Joseph, SB, Wilpitz, DC, Wang, X, Lusis, AJ, Collins, A, Hseuh, WA, Collins, JL, Tangirala, RK & Tontonoz, P 2007, 'Ligand activation of LXRβ reverses atherosclerosis and cellular cholesterol overload in mice lacking LXRα and apoE', Journal of Clinical Investigation, vol. 117, no. 8, pp. 2337-2346. https://doi.org/10.1172/JCI31909
Bradley, Michelle N. ; Hong, Cynthia ; Chen, Mingyi ; Joseph, Sean B. ; Wilpitz, Damien C. ; Wang, Xuping ; Lusis, Aldons J. ; Collins, Allan ; Hseuh, Willa A. ; Collins, Jon L. ; Tangirala, Rajendra K. ; Tontonoz, Peter. / Ligand activation of LXRβ reverses atherosclerosis and cellular cholesterol overload in mice lacking LXRα and apoE. In: Journal of Clinical Investigation. 2007 ; Vol. 117, No. 8. pp. 2337-2346.
@article{02d29f69e06847429d8bdc7d0dd5116a,
title = "Ligand activation of LXRβ reverses atherosclerosis and cellular cholesterol overload in mice lacking LXRα and apoE",
abstract = "Liver X receptors (LXRs) α and β are transcriptional regulators of cholesterol homeostasis and potential targets for the development of antiatherosclerosis drugs. However, the specific roles of individual LXR isotypes in atherosclerosis and the pharmacological effects of synthetic agonists remain unclear. Previous work has shown that mice lacking LXRα accumulate cholesterol in the liver but not in peripheral tissues. In striking contrast, we demonstrate here that LXRα-/-apoE-/- mice exhibit extreme cholesterol accumulation in peripheral tissues, a dramatic increase in whole-body cholesterol burden, and accelerated atherosclerosis. The phenotype of these mice suggests that the level of LXR pathway activation in macrophages achieved by LXRβ and endogenous ligand is unable to maintain homeostasis in the setting of hypercholesterolemia. Surprisingly, however, a highly efficacious synthetic agonist was able to compensate for the loss of LXRα. Treatment of LXRα-/-apoE-/- mice with synthetic LXR ligand ameliorates the cholesterol overload phenotype and reduces atherosclerosis. These observations indicate that LXRα has an essential role in maintaining peripheral cholesterol homeostasis in the context of hypercholesterolemia and provide in vivo support for drug development strategies targeting LXRβ.",
author = "Bradley, {Michelle N.} and Cynthia Hong and Mingyi Chen and Joseph, {Sean B.} and Wilpitz, {Damien C.} and Xuping Wang and Lusis, {Aldons J.} and Allan Collins and Hseuh, {Willa A.} and Collins, {Jon L.} and Tangirala, {Rajendra K.} and Peter Tontonoz",
year = "2007",
month = "8",
day = "1",
doi = "10.1172/JCI31909",
language = "English (US)",
volume = "117",
pages = "2337--2346",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "8",

}

TY - JOUR

T1 - Ligand activation of LXRβ reverses atherosclerosis and cellular cholesterol overload in mice lacking LXRα and apoE

AU - Bradley, Michelle N.

AU - Hong, Cynthia

AU - Chen, Mingyi

AU - Joseph, Sean B.

AU - Wilpitz, Damien C.

AU - Wang, Xuping

AU - Lusis, Aldons J.

AU - Collins, Allan

AU - Hseuh, Willa A.

AU - Collins, Jon L.

AU - Tangirala, Rajendra K.

AU - Tontonoz, Peter

PY - 2007/8/1

Y1 - 2007/8/1

N2 - Liver X receptors (LXRs) α and β are transcriptional regulators of cholesterol homeostasis and potential targets for the development of antiatherosclerosis drugs. However, the specific roles of individual LXR isotypes in atherosclerosis and the pharmacological effects of synthetic agonists remain unclear. Previous work has shown that mice lacking LXRα accumulate cholesterol in the liver but not in peripheral tissues. In striking contrast, we demonstrate here that LXRα-/-apoE-/- mice exhibit extreme cholesterol accumulation in peripheral tissues, a dramatic increase in whole-body cholesterol burden, and accelerated atherosclerosis. The phenotype of these mice suggests that the level of LXR pathway activation in macrophages achieved by LXRβ and endogenous ligand is unable to maintain homeostasis in the setting of hypercholesterolemia. Surprisingly, however, a highly efficacious synthetic agonist was able to compensate for the loss of LXRα. Treatment of LXRα-/-apoE-/- mice with synthetic LXR ligand ameliorates the cholesterol overload phenotype and reduces atherosclerosis. These observations indicate that LXRα has an essential role in maintaining peripheral cholesterol homeostasis in the context of hypercholesterolemia and provide in vivo support for drug development strategies targeting LXRβ.

AB - Liver X receptors (LXRs) α and β are transcriptional regulators of cholesterol homeostasis and potential targets for the development of antiatherosclerosis drugs. However, the specific roles of individual LXR isotypes in atherosclerosis and the pharmacological effects of synthetic agonists remain unclear. Previous work has shown that mice lacking LXRα accumulate cholesterol in the liver but not in peripheral tissues. In striking contrast, we demonstrate here that LXRα-/-apoE-/- mice exhibit extreme cholesterol accumulation in peripheral tissues, a dramatic increase in whole-body cholesterol burden, and accelerated atherosclerosis. The phenotype of these mice suggests that the level of LXR pathway activation in macrophages achieved by LXRβ and endogenous ligand is unable to maintain homeostasis in the setting of hypercholesterolemia. Surprisingly, however, a highly efficacious synthetic agonist was able to compensate for the loss of LXRα. Treatment of LXRα-/-apoE-/- mice with synthetic LXR ligand ameliorates the cholesterol overload phenotype and reduces atherosclerosis. These observations indicate that LXRα has an essential role in maintaining peripheral cholesterol homeostasis in the context of hypercholesterolemia and provide in vivo support for drug development strategies targeting LXRβ.

UR - http://www.scopus.com/inward/record.url?scp=34547652884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547652884&partnerID=8YFLogxK

U2 - 10.1172/JCI31909

DO - 10.1172/JCI31909

M3 - Article

C2 - 17657314

AN - SCOPUS:34547652884

VL - 117

SP - 2337

EP - 2346

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 8

ER -